Pathological bacterial translocation in cirrhosis: Pathophysiology, diagnosis and clinical implications

Liver International

Volumn 33, Issue 1, 2013, Pages 31-39

  Bellot, Pablo ^a,b   Francés, Rubén ^a,b   Such, Jose ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Bacterial DNA; Bacterial translocation; Cirrhosis; Portal hypertension

Indexed keywords

BACTERIAL DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE BINDING PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ADAPTIVE IMMUNITY; ASCITES; ASCITES FLUID; BACTERIAL OVERGROWTH; BACTERIAL TRANSLOCATION; BILE SECRETION; CELL JUNCTION; CLINICAL PRACTICE; ENDOTHELIAL DYSFUNCTION; ENDOTOXIN DETECTION; HEMORRHAGIC SHOCK; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; IMMUNE RESPONSE; INTESTINE EPITHELIUM; INTESTINE LYMPHATIC TISSUE; LIVER CIRRHOSIS; LIVER FAILURE; MESENTERY LYMPH NODE; NONHUMAN; OLIGOMERIZATION; PERITONEUM MACROPHAGE; PERMEABILITY; PEYER PATCH; PORTAL HYPERTENSION; REVIEW; SPECIES IDENTIFICATION; SYSTEMIC CIRCULATION;

ANIMALS; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL TRANSLOCATION; BACTERIAL TYPING TECHNIQUES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; DNA, BACTERIAL; ENDOTOXINS; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERTENSION, PORTAL; INTESTINE, SMALL; LIVER CIRRHOSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 84870841986     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12021     Document Type: Review

References (79)

1. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35: 140-8.
2. Borzio M, Salerno F, Piantoni L, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001; 33: 41-8.
3. Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246-56.
4. Goulis J, Armonis A, Patch D, et al. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998; 27: 1207-12.
5. Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun 1979; 23: 403-11.
6. Wiest R, Rath HC. Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut. Best Pract Res Clin Gastroenterol 2003; 17: 397-425.
7. de ME, Martinez J, Lozano B, et al. Detection and identification of bacterial DNA in serum from patients with acute pancreatitis. Gut 2005; 54: 1293-7.
8. Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34: 32-7.
9. Runyon BA, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. J Hepatol 1994; 21: 792-6.
10. Garcia-Tsao G, Lee FY, Barden GE, Cartun R, West AB. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 1995; 108: 1835-41.
11. Llovet JM, Bartoli R, March F, et al. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. J Hepatol 1998; 28: 307-13.
12. Garcia-Tsao G, Albillos A, Barden GE, West AB. Bacterial translocation in acute and chronic portal hypertension [see comments]. Hepatology 1993; 17: 1081-5.
13. Bellot P, Garcia-Pagan JC, Frances R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology 2010; 52: 2044-52.
14. Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 2008; 53: 1443-54.
15. Vanderhoof JA, Young RJ. Etiology and pathogenesis of bacterial overgrowth. Clinical manifestations and diagnosis of bacterial overgrowth. Treatment of bacterial overgrowth. Uptodate 2012; 20: 7.
16. Steffen EK, Berg RD. Relationship between cecal population levels of indigenous bacteria and translocation to the mesenteric lymph nodes. Infect Immun 1983; 39: 1252-9.
17. Perez-Paramo M, Munoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 2000; 31: 43-8.
18. Guarner C, Runyon BA, Young S, Heck M, Sheikh MY. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997; 26: 1372-8.
19. Casafont MF, De las Heras CG, Martin RL, et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci 1996; 41: 552-6.
20. Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1998; 28: 1187-90.
21. Bauer TM, Steinbruckner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001; 96: 2962-7.
22. Such J, Guardiola JV, de JJ, et al. Ultrastructural characteristics of distal duodenum mucosa in patients with cirrhosis. Eur J Gastroenterol Hepatol 2002; 14: 371-6.
23. Astaldi G, Strosselli E. Peroral biopsy of the intestinal mucosa in hepatic cirrhosis. Am J Dig Dis 1960; 5: 603-12.
24. Norman DA, Atkins JM, Seelig LL Jr, Gomez-Sanchez C, Krejs GJ. Water and electrolyte movement and mucosal morphology in the jejunum of patients with portal hypertension. Gastroenterology 1980; 79: 707-15.
25. Misra V, Misra SP, Dwivedi M, Gupta SC. Histomorphometric study of portal hypertensive enteropathy. Am J Clin Pathol 1997; 108: 652-7.
26. Bertok L. Bile acids in physico-chemical host defence. Pathophysiology 2004; 11: 139-45.
27. Clements WD, Parks R, Erwin P, et al. Role of the gut in the pathophysiology of extrahepatic biliary obstruction. Gut 1996; 39: 587-93.
28. Lorenzo-Zuniga V, Bartoli R, Planas R, et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 2003; 37: 551-7.
29. Pascual S, Such J, Esteban A, et al. Intestinal permeability is increased in patients with advanced cirrhosis. Hepatogastroenterology 2003; 50: 1482-6.
30. Campillo B, Pernet P, Bories PN, et al. Intestinal permeability in liver cirrhosis: relationship with severe septic complications. Eur J Gastroenterol Hepatol 1999; 11: 755-9.
31. Ramachandran A, Prabhu R, Thomas S, et al. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. Hepatology 2002; 35: 622-9.
32. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18: 1139-43.
33. Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264-74.
34. Llovet JM, Bartoli R, Planas R, et al. Selective intestinal decontamination with norfloxacin reduces bacterial translocation in ascitic cirrhotic rats exposed to hemorrhagic shock. Hepatology 1996; 23: 781-7.
35. Appenrodt B, Grunhage F, Gentemann MG, et al. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 2010; 51: 1327-33.
36. Garcia-Gonzalez M, Boixeda D, Herrero D, Burgaleta C. Effect of granulocyte-macrophage colony-stimulating factor on leukocyte function in cirrhosis. Gastroenterology 1993; 105: 527-31.
37. Rajkovic IA, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology 1986; 6: 252-62.
38. Such J, Guarner C, Enriquez J, et al. Low C3 in cirrhotic ascites predisposes to spontaneous bacterial peritonitis. J Hepatol 1988; 6: 80-4.
39. Rimola A, Soto R, Bory F, et al. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 1984; 4: 53-8.
40. Inamura T, Miura S, Tsuzuki Y, et al. Alteration of intestinal intraepithelial lymphocytes and increased bacterial translocation in a murine model of cirrhosis. Immunol Lett 2003; 90: 3-11.
41. Unno N, Wang H, Menconi MJ, et al. Inhibition of inducible nitric oxide synthase ameliorates endotoxin-induced gut mucosal barrier dysfunction in rats. Gastroenterology 1997; 113: 1246-57.
42. Frances R, Chiva M, Sanchez E, et al. Bacterial translocation is downregulated by anti-TNF-alpha monoclonal antibody administration in rats with cirrhosis and ascites. J Hepatol 2007; 46: 797-803.
43. Panes J, Perez-del-Pulgar S, Casadevall M, et al. Impaired mesenteric leukocyte recruitment in experimental portal hypertension in the rat. Hepatology 1999; 30: 445-53.
44. Opal SM. The clinical relevance of endotoxin in human sepsis: a critical analysis. J Endotoxin Res 2002; 8: 473-6.
45. Stadlbauer V, Davies NA, Wright G, Jalan R. Endotoxin measures in patients' sample: how valid are the results? J Hepatol 2007; 47: 726-7.
46. Albillos A, de la HA, Gonzalez M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-17.
47. Albillos A, de la Hera A, Alvarez-Mon M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet 2004; 363: 1608-10.
48. Gonzalez-Navajas JM, Bellot P, Frances R, et al. Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. J Hepatol 2008; 48: 61-7.
49. Shimizu T, Tani T, Endo Y, et al. Elevation of plasma peptidoglycan and peripheral blood neutrophil activation during hemorrhagic shock: plasma peptidoglycan reflects bacterial translocation and may affect neutrophil activation. Crit Care Med 2002; 30: 77-82.
50. Such J, Frances R, Munoz C, et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002; 36: 135-41.
51. Frances R, Benlloch S, Zapater P, et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology 2004; 39: 484-91.
52. Guarner C, Gonzalez-Navajas JM, Sanchez E, et al. The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology 2006; 44: 633-9.
53. Serste T, Bert F, Leflon-Guibout V, et al. Detection of bacterial DNA in serum and ascitic fluid of asymptomatic outpatients with cirrhosis and non-neutrocytic ascites. Liver Int 2011; 31: 494-8.
54. Bruns T, Sachse S, Straube E, et al. Identification of bacterial DNA in neutrocytic and non-neutrocytic cirrhotic ascites by means of a multiplex polymerase chain reaction. Liver Int 2009; 29: 1206-14.
55. Riordan SM, Skinner N, Nagree A, et al. Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology 2003; 37: 1154-64.
56. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422-33.
57. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-60.
58. Frances R, Munoz C, Zapater P, et al. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut 2004; 53: 860-4.
59. Frances R, Zapater P, Gonzalez-Navajas JM, et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008; 47: 978-85.
60. Wiest R, Cadelina G, Milstien S, et al. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology 2003; 38: 1508-15.
61. Shah N, Dhar D, El Zahraa MF, et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression. J Hepatol 2012; 56: 1047-53.
62. Angeli P, Brun P, Cesari M, et al. Prevalence of bacterial DNA in patients with cirrhosis and refractory Ascites and its role in the development of cardiac and renal dysfunctions. Hepatology 2010; 52(4 (Suppl)): 342A.
63. Kalambokis GN, Mouzaki A, Rodi M, et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol 2012; 10: 815-8.
64. Fernandez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-24.
65. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 1996; 24: 233-40.
66. Yamamoto S, Burman HP, O'Donnell CP, Cahill PA, Robotham JL. Endothelin causes portal and pulmonary hypertension in porcine endotoxemic shock. Am J Physiol 1997; 272(3 Pt 2): H1239-49.
67. Pannen BH, Bauer M, Zhang JX, Robotham JL, Clemens MG. Endotoxin pretreatment enhances portal venous contractile response to endothelin-1. Am J Physiol 1996; 270(1 Pt 2): H7-15.
68. Baveja R, Keller S, Yokoyama Y, et al. LPS-induced imbalanced expression of hepatic vascular stress genes in cirrhosis: possible mechanism of increased susceptibility to endotoxemia. Shock 2002; 17: 316-21.
69. Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs AK. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005; 54: 556-63.
70. Vaquero J, Polson J, Chung C, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 2003; 125: 755-64.
71. Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004; 40: 247-54.
72. Jun DW, Kim KT, Lee OY, et al. Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. Dig Dis Sci 2010; 55: 1465-71.
73. Gupta A, Dhiman RK, Kumari S, et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 2010; 53: 849-55.
74. Sidhu SS, Goyal O, Mishra BP, et al. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011; 106: 307-16.
75. Bajaj JS, Heuman DM, Wade JB, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011; 140: 478-87.
76. Zapater P, Frances R, Gonzalez-Navajas JM, et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology 2008; 48: 1924-31.
77. Terg R, Fassio E, Guevara M, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol 2008; 48: 774-9.
78. Kalambokis GN, Tsianos EV. Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis. Hepatology 2012; 55: 655-6.
79. Kalambokis GN, Mouzaki A, Rodi M, Tsianos EV. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia. Liver Int 2012; 32: 467-75.